Premium
P2‐447: Liposomes functionalized with acidic lipids rescue Aβ‐induced toxicity in murine neuroblastoma cells
Author(s) -
Bereczki Erika,
Re Francesca,
Masserini Massimo,
Winblad Bengt,
Pei Jin Jing
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.1319
Subject(s) - phosphatidic acid , viability assay , liposome , cardiolipin , toxicity , western blot , cell culture , chemistry , mtt assay , cell , biochemistry , microbiology and biotechnology , pharmacology , biology , phospholipid , genetics , organic chemistry , membrane , gene
The loss of synapses and neurons in Alzheimer's disease (AD) is thought to be at least partly induced by toxic species formed by the amyloid beta (Aβ) peptide; therefore, therapeutics aimed at reducing Aβ toxicity could be of clinical use for treatment of AD. Liposomes are suitable vehicles for therapeutic agents and imaging probes, and a promising way of targeting the various Aβ forms. We tested liposomes functionalized with phosphatidic acid, cardiolipin, or GM1 ganglioside, previously shown to have high Aβ-binding capacity. Mimicking Aβ-induced toxicity in mouse neuroblastoma cell lines, combined with administration of cell viability-modulating agents, we observed that functionalized liposomes rescued cell viability to different extents. We also detected rescue of the imbalance of GSK-3β and PP2A activity, and reduction in tau phosphorylation. Thus, these liposomes appear particularly suitable for implementing further therapeutic strategies for AD. From the Clinical Editor: In this paper, Bereczki and her colleagues present functionalized liposomes targeting amyloid beta peptide, which may pave the way to disease modifying agent development in neurodegenerative conditions related to amyloid beta accumulation, including Alzheimer’s disease. © 2011 Elsevier Inc. All rights reserved.